Finally, the observation that depleting USP17, in combination with gefitinib, triggers EGFRWT NSCLC cells to undergo apoptosis, indicates targeting USP17 in combination with an EGFR TKI could greatly expand the efficacy of these drugs in the NSCLC patient population. This evidence concerns the gene EGFR and non-small cell lung carcinoma.